Christoph E. Heilig

Christoph E. Heilig

Auto-generated profile, based on publicly available information

Christoph E. Heilig

Division of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2021 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
PHPeter Horak
Peter Horak
CHChristoph Heining
Christoph Heining
SKSimon Kreutzfeldt
Simon Kreutzfeldt
BHBarbara Hutter
Barbara Hutter
AMAndreas Mock
Andreas Mock
SFStefan Fröhling
Stefan Fröhling
The clinical relevance of comprehensive molecular analysis in rare cancers is not established. We analyzed the molecular profiles and clinical outcomes of 1,310 patients (rare cancers, 75.5%) enrolled in a prospective observational study by the German Cancer Consortium that applies whole-genome/exome and RNA sequencing to inform the care of adults with incurable cancers. On the basis of 472 single and six composite biomarkers, a cross-institutional molecular tumor board provided evidence-based management recommendations, including diagnostic reevaluation, genetic counseling, and experimental treatment, in 88% of cases. Recommended therapies were administered in 362 of 1,138 patients (31.8%) and resulted in significantly improved overall response and disease control rates (23.9% and 55.3%) compared with previous therapies, translating into a progression-free survival ratio >1.3 in 35.7% of patients. These data demonstrate the benefit of molecular stratification in rare cancers and represent a resource that may promote clinical trial access and drug approvals in this underserved patient population.Significance: Rare cancers are difficult to treat; in particular, molecular pathogenesis–oriented medical therapies are often lacking. This study shows that whole-genome/exome and RNA sequencing enables molecularly informed treatments that lead to clinical benefit in a substantial proportion of patients with advanced rare cancers and paves the way for future clinical trials.See related commentary by Eggermont et al., p. 2677.This article is highlighted in the In This Issue feature, p. 2659

28 September 2006 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
NBNiko K. Bender
Niko K. Bender
CHChristoph E. Heilig
Christoph E. Heilig
BDBenjamin Dröll
Benjamin Dröll
JWJessica Wohlgemuth
Jessica Wohlgemuth
FAFranz-Paul Armbruster
Franz-Paul Armbruster
BHBernhard Heilig
Bernhard Heilig

8 May 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
NVNatalia Voronina
Natalia Voronina
JWJohn K. L. Wong
John K. L. Wong
DHDaniel Hübschmann
Daniel Hübschmann
MHMario Hlevnjak
Mario Hlevnjak
SUSebastian Uhrig
Sebastian Uhrig
AEAurélie Ernst
Aurélie Ernst
Chromothripsis is a recently identified mutational phenomenon, by which a presumably single catastrophic event generates extensive genomic rearrangements of one or a few chromosome(s). Considered as an early event in tumour development, this form of genome instability plays a prominent role in tumour onset. Chromothripsis prevalence might have been underestimated when using low-resolution methods, and pan-cancer studies based on sequencing are rare. Here we analyse chromothripsis in 28 tumour types covering all major adult cancers (634 tumours, 316 whole-genome and 318 whole-exome sequences). We show that chromothripsis affects a substantial proportion of human cancers, with a prevalence of 49% across all cases. Chromothripsis generates entity-specific genomic alterations driving tumour development, including clinically relevant druggable fusions. Chromothripsis is linked with specific telomere patterns and univocal mutational signatures in distinct tumour entities. Longitudinal analysis of chromothriptic patterns in 24 matched tumour pairs reveals insights in the clonal evolution of tumours with chromothripsis.

22 April 2019 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
JLJonas Leichsenring
Jonas Leichsenring
PHPeter Horak
Peter Horak
SKSimon Kreutzfeldt
Simon Kreutzfeldt
CHChristoph Heining
Christoph Heining
PCPetros Christopoulos
Petros Christopoulos
Albrecht  StenzingerAlbrecht Stenzinger
Albrecht Stenzinger

9 April 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
SGStefan Gröschel
Stefan Gröschel
DHDaniel Hübschmann
Daniel Hübschmann
FRFrancesco Raimondi
Francesco Raimondi
PHPeter Horak
Peter Horak
GWGregor Warsow
Gregor Warsow
SFStefan Fröhling
Stefan Fröhling
Chordomas are rare bone tumors with few therapeutic options. Here we show, using whole-exome and genome sequencing within a precision oncology program, that advanced chordomas (n = 11) may be characterized by genomic patterns indicative of defective homologous recombination (HR) DNA repair and alterations affecting HR-related genes, including, for example, deletions and pathogenic germline variants of BRCA2, NBN, and CHEK2. A mutational signature associated with HR deficiency was significantly enriched in 72.7% of samples and co-occurred with genomic instability. The poly(ADP-ribose) polymerase (PARP) inhibitor olaparib, which is preferentially toxic to HR-incompetent cells, led to prolonged clinical benefit in a patient with refractory chordoma, and whole-genome analysis at progression revealed a PARP1 p.T910A mutation predicted to disrupt the autoinhibitory PARP1 helical domain. These findings uncover a therapeutic opportunity in chordoma that warrants further exploration, and provide insight into the mechanisms underlying PARP inhibitor resistance.

22 June 2009 in Journal of Cell Biology
Verified
Journal Article
Open access
ATAlexandra Tibelius
Alexandra Tibelius
JMJoachim Marhold
Joachim Marhold
HZHanswalter Zentgraf
Hanswalter Zentgraf
CHChristoph E. Heilig
Christoph E. Heilig
HNHeidemarie Neitzel
Heidemarie Neitzel
AKAlwin Krämer
Alwin Krämer
Primary microcephaly, Seckel syndrome, and microcephalic osteodysplastic primordial dwarfism type II (MOPD II) are disorders exhibiting marked microcephaly, with small brain sizes reflecting reduced neuron production during fetal life. Although primary microcephaly can be caused by mutations in microcephalin (MCPH1), cells from patients with Seckel syndrome and MOPD II harbor mutations in ataxia telangiectasia and Rad3 related (ATR) or pericentrin (PCNT), leading to disturbed ATR signaling. In this study, we show that a lack of MCPH1 or PCNT results in a loss of Chk1 from centrosomes with subsequently deregulated activation of centrosomal cyclin B–Cdk1.